Mechanistically, the crosstalk between CatD and ASMase confers resistance to gemcitabine, and if confirmed in a prospective, randomized trial, CatD can be used as either a biomarker in the setting of precision medicine or as a novel drug target for the treatment of pancreatic cancer. This evidence concerns the gene SMPD1 and pancreatic neoplasm.